

VYLOY™ (ZOLBETUXIMAB) JAPAN REGULATORY UPDATE



March 29, 2024 (JST)

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

In this material, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. A number of factors could cause actual results to differ materially from those discussed in the forward-looking statements. Such factors include, but are not limited to: (i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue to effectively research and develop products accepted by customers in highly competitive markets, and (vi) infringements of Astellas' intellectual property rights by third parties.

Information about pharmaceutical products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.

The safety and efficacy of zolbetuximab has been assessed by the PMDA and approved for CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer. VYLOY is used in combination with chemotherapy for patients whose tumors are human epidermal growth factor receptor 2 (HER2)-negative. In other markets, zolbetuximab is an investigational compound in clinical development. The safety and efficacy of zolbetuximab is being assessed by other Regulatory Authorities. There is no guarantee it will receive regulatory approval or become commercially available in all markets.

本資料には、医薬品に関する情報が含まれています。それらの医薬品は、すべての国で発売されているとは限らず、また、国によって商標、効能・効果、用法・用量等が異なる可能性もあります。ここに記載されている内容は、株主や投資家の皆さまのための情報開示を目的としており、開発品を含むいかなる医療用医薬品の宣伝広告、医学的アドバイスを意図するものではありません。

- I Gastric Cancer Disease State
- II VYLOY Product Profile & Commercial Strategy
- III Future Plans
- IV Q&A

Presenter




John Demaree
Head, Strategic Brand Marketing, Oncology

Q&A Participants



Tomoko Nakajima, Ph.D.
Asset Lead, zolbetuximab




Shelley Shaw
Global Brand Lead, zolbetuximab


GASTRIC CANCER DISEASE STATE

GASTRIC CANCER HAS A DEVASTATING IMPACT ON PATIENTS

~1 Million Cases of Gastric Cancer Diagnosed Globally in 2022¹




3rd Deadliest Cancer in Japan¹



Effective Treatment Options Are Limited

PATIENTS WITH CLDN18.2 POSITIVE, UNRESECTABLE, ADVANCED OR RECURRENT GASTRIC CANCER NEED NEW TREATMENT OPTIONS



78% of 1L advanced gastric cancer population is HER2-negative³



In Japan, **chemotherapy ± CPI** is the current standard of care⁴





Oncologists are seeking new treatment options that may improve survival outcomes⁵


CPI: Checkpoint inhibitors

CLDN18.2 IS A NOVEL BIOMARKER IN ADVANCED GASTRIC CANCER


High prevalence and strength of clinical data provide strong reason to test for CLDN18.2 positivity




Confined in Healthy Tissue⁸



Retained and Exposed in Malignant Transformation⁸




Maintained in Metastatic Progression⁸



*CLDN18.2 positive is defined as $\geq 75\%$ tumor cells showing moderate-to-strong membranous CLDN18 staining^{6,7}


**Treating HCPs include oncologists, digestive surgeons and gastroenterologists

DIAGNOSTIC TESTING EDUCATION RESOURCES TO SUPPORT PATHOLOGISTS



Claudin182.JP

Unique peer-to-peer education platform on biomarker testing for pathologists



VYLOY PRODUCT PROFILE & COMMERCIAL STRATEGY

THE JOURNEY OF VYLOY



*Phase 1 and Phase 2 studies were conducted previously

**Global regulatory submissions to date include U.S., Japan, China, Europe, among other markets

IDENTIFYING POTENTIAL CANDIDATES FOR VYLOY




There are approximately 400,000⁹ patients diagnosed globally with Stage IV mGC/GEJ**


Biomarker Testing

HER2 Status


CLDN18.2 Status



**Tested for HER2
(and CLDN18.2 in future)**



HER2-negative




CLDN18.2 positive

*Percentages represent global weighted averages

**In Japan, the gastric cancer indication includes gastroesophageal junction (GEJ) adenocarcinoma

VYLOY PROVIDES A TARGETED TREATMENT OPTION

13




1. VYLOY is indicated for CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer

2. VYLOY is **first and only approved** CLDN18.2-targeted therapy


3. VYLOY can be used in eligible patients **regardless of combined positive score (CPS)**

DATA FROM PIVOTAL PHASE 3 TRIALS SUPPORTED APPROVAL: SPOTLIGHT⁶

PROGRESSION-FREE SURVIVAL (PRIMARY ENDPOINT, ITT)*



OVERALL SURVIVAL (KEY SECONDARY ENDPOINT, ITT)




Median OS was the longest OS observed in a global Phase 3 trial in this patient population.^{11,12}


*PFS was assessed per RECIST v1.1 by IRC
mFOLFOX6: 5-FU, leucovorin and oxaliplatin; PFS: Progression-free survival; OS: Overall survival

DATA FROM PIVOTAL PHASE 3 TRIALS SUPPORTED APPROVAL: GLOW⁷

PROGRESSION-FREE SURVIVAL (PRIMARY ENDPOINT, ITT)*



OVERALL SURVIVAL (SECONDARY ENDPOINT, ITT)



SPOTLIGHT and GLOW had similar overall survival hazard ratios, validating the effectiveness of zolbetuximab combined with chemotherapy.^{6,7}

*PFS was assessed per RECIST v1.1 by IRC
CAPOX: Capecitabine and oxaliplatin; PFS: Progression-free survival; OS: Overall survival

SAFETY DATA FROM SPOTLIGHT AND GLOW

SPOTLIGHT

Incidence of serious TEAEs* was similar between both arms (44.8% vs. 43.5%)⁶

Most frequent TEAEs in the VYLOY versus control arms:

- Nausea (82.4% vs. 60.8%)
- Vomiting (67.4% vs. 35.6%)
- Decreased appetite (47.0% vs. 33.5%)

GLOW

Incidence of serious TEAEs was similar between both arms (47.2% vs. 49.8%)⁷

Most frequent TEAEs in the VYLOY versus control arms:

- Nausea (68.5% vs. 50.2%)
- Vomiting (66.1% vs. 30.9%)
- Decreased appetite (41.3% vs. 33.7%)

*Treatment emergent adverse events

DR. KOHEI SHITARA DISCUSSES SIGNIFICANCE OF MHLW APPROVAL OF VYLOY

17

Projection Only

MAXIMIZING THE VALUE OF VYLOY: LEVERAGING ONCOLOGY EXPERTISE



Successfully launching oncology products into areas of high unmet need




Building market leadership



Creating strong relationships in oncology



Preparing experienced, knowledgeable, and agile sales force for readiness upon launch



ACTIVATING LABS FOR IMMEDIATE TESTING FOR CLDN18.2 POSITIVITY IN JAPAN

Recently, VENTANA® CLDN18 (43-14A) Rx Dx Assay, developed by Roche, was approved as an IHC companion diagnostic.



At VYLOY launch, strategic partnerships with the top 3 central labs and major cancer centers will ensure national availability to testing for all patients, providing coverage throughout Japan.



Post-VYLOY launch, both HQ and sales team will collaborate with labs to increase awareness of and broaden local access to testing.



SIRIL
Communication for Health
20 Labs



BML
60 Labs


LSIメディエンス
60 Labs



FUTURE PLANS


GLOBAL LAUNCH PLAN

 **Global Launch: VYLOY + Roche VENTANA CDx**

 **~50 VYLOY country launches planned¹³**

 **Multiple launches in Asian countries where disease incidence is highest¹**

Anticipated Approval Timings*



*Global regulatory submissions to date include U.S., China, and Europe, among others

LOOKING AHEAD TO A POTENTIAL PANCREATIC CANCER INDICATION

22




4th

Leading cause of
cancer death in
Japan¹⁴



<5%



5-year survival
globally for patients at
the metastatic stage¹⁵

Phase 2 registrational trial in metastatic pancreatic adenocarcinoma is in progress¹⁶



Potential pancreatic cancer indication represents significant upside potential for the VYLOY global sales forecast



*Claudin 18.2 positive is defined as $\geq 75\%$ tumor cells showing moderate-to-strong membranous CLDN18 staining

KEY TAKEAWAYS



CLDN18.2 is a novel and highly prevalent predictive biomarker in advanced gastric cancer that can be readily detected via IHC^{6,7}



VYLOY is approved for patients with HER2-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer, which is the third deadliest in Japan¹



VENTANA CLDN18 (43-14A) RxDx Assay developed by Roche is approved as an IHC companion diagnostic for VYLOY to help determine CLDN18.2 status

VYLOY is also being evaluated in pancreatic cancer,¹⁶ which is expected to remain the fourth deadliest cancer in Japan¹⁴

Thank You



APPENDIX

REFERENCES

1. Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available at <https://gco.iarc.fr/today>.
2. Yashima K, Shabana M, Kurumi H, Kawaguchi K, Isomoto H. Gastric Cancer Screening in Japan: A Narrative Review. *J Clin Med*. 2022 Jul 26;11(15):4337. doi: 10.3390/jcm11154337. PMID: 35893424; PMCID: PMC9332545.
3. Van Cutsem E, Bang YJ, Feng-Yi F, et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. *Gastric Cancer* 2015;18(3):476-84.
4. INTERNAL: Zolbetuximab ATU Marketing Research, November 2023.
5. INTERNAL: Zolbetuximab FY24 Integrated Global Brand Plan Situational Analysis, February 2023.
6. Shitara K, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. *The Lancet*. Published online April 14, 2023; S0140-6736(23)00620-7.
7. Shah, M.A., Shitara, K., Ajani, J.A. et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial. *Nat Med* (2023). <https://doi.org/10.1038/s41591-023-02465-7>.
8. GastricCancerBiomarkers.com <https://www.gastriccancerbiomarkers.com/content/dam/globalbrands/zolbe/na/us/en/documents/074-0896-PM-US-Gastric-DSA-iVA.pdf>
9. EU5, US, Japan and China KANTAR report 2020.
10. Ipsos GC EU5, US and Japan 2020; China Kantar report 2020.
11. Rha SY, Oh DY, Yañez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fernández MG, Li J, Lowery MA, Çil T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2023 Nov;24(11):1181-1195.
12. Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Campos Bragagnoli A, Liu T, Schenker M, Yanez P, Tehfe M, Kowalyszyn R, Karamouzian MV, Bruges R, Zander T, Pazo-Cid R, Hitre E, Feeney K, Cleary JM, Poulart V, Cullen D, Lei M, Xiao H, Kondo K, Li M, Ajani JA. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. *Lancet*. 2021 Jul 3;398(10294):27-40.
13. INTERNAL: Zolbetuximab FY24 Integrated Global Brand Plan, August 2023.
14. Cerner Enviza CancerMPact Treatment Architecture Japan Report.
15. ClinicalTrials.gov. A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma. Available at <https://clinicaltrials.gov/study/NCT03816163>. Accessed 11-29-2023.